trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate, causing intracellular calcium release. Studies from several different cell types have shown that AII induces tyrosine phosphorylation of multiple proteins including p44/p56SHC, the Jak family proteins Jak2 and Tyk2 and Focal Adhesion Kinase (FAK125) and AII can stimulate activity of intracellular kinases including Extracellular Signal Regulated Kinases (ERKs) and Jun N-terminal Kinases (JNKs). Transcription factors implicated in proliferative signaling by AII include the STAT proteins and members of the Activator Protein -1 (AP-1 complex). Delayed early genes induced by AII in adrenal cortical cells involved in cellular proliferation and survival include the cyclin D1 gene product, a labile sensor of mitogenic stimulation which plays a critical role in proliferative signaling and cell-cycle control. In recent studies, AII induced expression of the human homologue of Xenopus XPMC2 (HX-PMC2), implicating its role in the AII proliferating/survival response. In order to understand the complex coordination of genomic response to AII we have used gridded cDNA microarray to identify differential expression profiles induced by AII in the H295R human adrenocortical cell line, which expresses AII receptors predominantly of the AT1 subclass. Of the 5,000 human genes interrogated, 1086 revealed transcriptional induction or repression profiles, 27% were ESTs, 5% novel sequences and 68% known genes. Of the known identified genes, 16% are transcriptional regulators and 7.5% are involved in cell cycle control and DNA synthesis. Correlation of expression profile patterns with functional roles demonstrates coordinated interactions between genes governing cellular biogenesis, metabolism and intracellular transport. Identification of coordinated patterns of functionally related target genes provides a platform for understanding the mechanisms by which AII governs growth survival and cellular proliferation.
P-351 ANGIOTENSIN II STIMULATES NADPH-OXIDASE AND PHOSPHOLIPASE A2 ACTIVITIES IN PHAGOCYTIC CELLS. A POSSIBLE ROLE OF PYK2 AND MAP-KINASES, ERK AND P38, IN ANGIOTENSIN II-SIGNALING
Inbal Talya Wolak, Ira Lubarsky, Rachel Levy, Esther Paran. 1 Clinical Biochemistry, Faculty of Health Sciences, Israel, 2 Hypertension Unit, Soroka Medical center, Israel It has been suggested that the binding of angiotensin II to AT1 receptors activates a cascade of events that leads to stimulation of oxidative stress, the products of which possess remarkable vasoconstrictive qualities. The major enzyme-producing oxidative radical is the enzymatic complex NADPH-oxidase. The effect of angiotensin II on activation of NADPHoxidase in monocyte and granulocyte from normotensive volunteers and the signaling pathways leading to its activity were investigated. Angiotensin II stimulated a dose-dependent activation of NADPH oxidase in both peripheral blood monocytes and granulocytes, with higher activity obtained in monocytes. Similarly, a dose-dependent activation of NADPH oxidase was demonstrated in the myeloid cell-line PLB-985 differentiated towards neutrophil or monocyte lineages, with higher efficiency observed in the monocytic-like cells. The selective AT1 receptor antagonist, losartan, inhibited NADPH-oxidase activity stimulated by angiotensin II. A high correlation between phospholipase A2 and NADPH-oxidase activities were obtained in angiotensin II-stimulated monocytes, neutrophils or differentiated PLB-985 cells. These results are in accordance with our previous studies demonstrating the essential requirement of cytosolic phospholipase A2 for activation of NADPHoxidase. Potential upstream components of phospholipase A2 activation were investigated. Angiotensin II stimulated a dose and time-dependent activation of the cytosolic tyrosine kinase, Pyk2, and the MAP-kinases, ERK 1/2 and p38, in differentiated PLB-985 cells. Our results demon-strate the ability of angiotensin II to stimulate phagocytic cells and suggest a possible role of these cells in the pathology of hypertensive disease via the formation of inflammatory mediators.
Key Words: NADPH-oxidase, Phospholipase A2, Angiotensin II M. C. Lansang, S. Y. Osei, C. Coletti, J. Krupinski, N. K. Hollenberg. 1 Brigham and Women's Hospital and Harvard Medical School, Boston, MA, United States Hyperglycemia-induced RAS activation has been observed in normal and diabetic humans. The main objective was to determine whether this phenomenon reflected the physical or metabolic effects of glucose loading. First, an animal model was developed. Using CD rats, the relationship between candesartan dose and renal vascular response during hyperglycemia was examined by giving sequential, increasing doses of candesartan (0.01-3.0 mg/kg i.v.) 30 min apart in the presence of a continuous dextrose 20% in water (D20W) infusion. The 0.1 mg/kg dose produced a maximal renal blood flow (RBF) response and was used thereafter. Another set of animals was then infused with normal saline (NS), dextrose 5% in water (D5W) or D20W for 2 hrs followed by candesartan 0.1 mg/kg i.v. Finally, the responses to candesartan during infusion of D20W and of 2-deoxyglucose (2DG)-an analog of glucose that acts as a competitive inhibitor of the glycolytic enzyme hexokinasewere compared. RBF, BP, blood glucose and urine glucose were monitored.
P-352 THE MECHANISM OF HYPERGLYCEMIA-INDUCED RAS ACTIVATION: CONTRIBUTION OF METABOLIC PATHWAYS
There was no significant RBF response to candesartan in either the NS group (6.0 Ϯ 0.5 mL/min/g kidney to 6.2 Ϯ 0.5; pϭ0.216) or the D5W group (7.6 Ϯ 1.2 to 7.6 Ϯ 1.4; pϭ0.965), whereas there was a significant response in the D20W group (6.6 Ϯ 0.6 to 7.5 Ϯ 0.7; pϭ0.002). The RBF response was significantly enhanced by D20W compared to 2DG (delta RBF: 0.82 Ϯ 0.22 vs -0.04 Ϯ 0.26; pϭ0.050). BP, blood glucose and urine glucose were similar in the 2 groups. Glucose acts, at least in part, through intracellular utilization to induce RAS activation, as manifested by an enhanced renal vascular response to an AngII antagonist.
Key Words: renin-angiotensin system, hyperglycemia, 2-deoxyglucose Gary Weisinger, Rona Limor, Esther Knoll, Fortuna Kohen, Vera Schinder, Michael Firer, Peter Krieg, Naftali Stern. 1 Endocrinology, Metabolism, Hypertension, Sourasky Medical Center, Tel Aviv, Israel, 2 Biological Regulation, Weizman Institute, Rehovot, Israel, 3 EM Unit, Weizman Institute, Rehovot, Israel, 4 Research Institute, College of Judea and Sameria, Ariel, Israel, 5 Tumor Regulation, DKFZ, Heidelberg, Germany
P-353 ANGIOTENSIN II INDUCES TRANSPORT OF CYTOPLASMIC LIPOXYGENASE PROTEINS TO ACTIN FIBERS
We have previously reported that angiotensin-II increases the formation of 12-and 15-hydroxyeicosatetraenoic acid (HETE) in cultured human umbilical artery smooth muscle cells (VSMC). We further reported that 12-lipoxygenase (LO) inhibitors block angiotensin-II induced vasoconstriction invitro and in vivo and lower blood pressure in SHR and renovasailor hypertensive rats. To gain insights into the mechanisms underlying these effects we set out to localize the 12LO protein in primary human arterial tissue and VSMC. First, we characterized the expression of a human platelet type 12LO mRNA in VSMC. Second, we developed a polyclonal antibody directed to a 24 amino acid peptide corresponding to exon 4 region of the expressed 12LO gene. Third, upon Western analysis of protein extracts derived from vascular human placental artery smooth muscle cells (VSMC), bands of 74 (major), 62 (major), 110 (minor) and 34 kDa were visualized. Fourth, immunohistochemical analysis of these same cells in culture or within whole placental artery or cultured human mammary artery smooth muscle cells showed a clear cytoplasmic localization. Fifth, on electron microscopy using the affinity-purified exon 4, 12-LO antibody with immunogold, 12-LO was found primarily localized between the cytoplasmic muscle fibrils of VSMC, but not in the body of the nucleus, mitochondria and endoplasmic recticulim. Finally, upon angiotensin-II treatment of cultured VSMC, 12-LO was found by immunoprecipitation, to bind to ␣-actin, a component of the cytoplasmic muscle fibrils, which was blocked by pretreatment of with the 12-LO inhibitors, baicalien or esculetine. Angiotensin-II also decreased the association of 15-LO (type 2) with ␣-actin, albeit with different kinetics. Moreover, the dissociation of 15-LO, but not the binding of 12-LO to ␣-actin coincided with the tyrosine phosphorylation of this protein. In summary, cytoplasmic juxtafibrillar LO proteins associate with ␣-actin in response to angiotensin-II which can be blocked by LO inhibitors. These observations suggest a previously unrecognized association between angiotensin-II dependent vasoconstriction, LO protein-␣-actin interactions and fatty acid oxidation in human VSMC. Maria Cristina Bravi, Antonella Armiento, Giovambattista Desideri, Claudio Ferri, Giancarlo De Mattia. 1 Internal Medicine, Univesrity of Rome "La Sapienza", Rome, Italy, 2 Internal Medicine and Public Health, University of l'Aquila, l'Aquila, Italy As is known, vascular smooth muscle cell migration is stimulated by angiotensin II. To evaluate the possible peptide effect on human vascular endothelial cell (HUVEC) migration, HUVECs were obtained from umbilical cord veins and cultured in Dulbecco's HAT medium. After 4-5 passages HUVECs were seeded at high density in Boyden chambers modified by the insertion of a polyethyleneterephthalate membrane (porosity ϭ 8 m). HUVEC migration was then quantified as the mean number of migrated cells observed in five high-power fields. In further experiments, "endothelial wound repair" was also assessed, i.e. "wounds" were inflicted by dragging a sterile pipette tip across cell monolayers and the number of cells migrating into the "wounded area" after various time up to 12 hours was quantified by light microscopy. Results: the addition of angiotensin II at various concentrations reduced HUVEC migration by at least 50%. Such effect was abolished by the AT1 receptor inhibitor losartan and the antioxidant N-acetyl-L-cysteine (NAC). In contrast, AT2 receptor inhibition was completely ineffective. Angiotensin II also reduced the so-called "wound repair", i.e. markedly reduced HUVEC ability to migrate into wound areas and delayed wound closure. Also in this case, the angiotensin II effect was blocked by losartan and NAC but not AT2 receptor inhibition. In conclusion, angiotensin II strongly reduces HUVEC migration in vitro. This effect of angiotensin II is inhibited by losartan and NAC, suggesting oxidative mechanisms are activated by the peptide in the vascular endothelium and might markedly affect endothelial response to injuries.
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